Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

65,437 trials

Phase 2 N=15 A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Solid Tumor Malignancy · Hematologic Malignancy · Leukemia
Primary: Number of Participants With Grades 1-5 Solicited (Expected) and/or Unsolicited (Unexpected) Adverse Events (AE's): Initial Phase — 0; 0; 1; 0 Participants
National Cancer Institute (NCI) Results Aug 2024 15.8% serious AE View details

N/A N=80 Hyperthermic Yoga for Depressive Symptoms

Depression · Major Depressive Disorder
Primary: Depressive Symptoms as Measured by the Inventory of Depressive Symptomatology - Clinician Rated (IDS-CR) — 17.93; 29.63 units on a scale
Massachusetts General Hospital Results Aug 2024 0.0% serious AE View details

N/A N=59 Cognitive Training in the Treatment of AUD

Alcohol Use Disorder Cognitive Decline
Primary: Days of Heavy Alcohol Use Assessed by Weekly Time Line Follow-back and Breathalyzer — 5.49; 3.0 Days — p=<.05
VA Office of Research and Development Results Aug 2024 0.0% serious AE View details

N/A N=50 Enhanced Problem-Solving Training

Brain Concussion
Primary: Brief Symptom Inventory-18 (BSI-18) Global Severity Index T-Score — 64.21; 65.26; 66.8; 61.35 units on a scale — p=.04
VA Office of Research and Development Results Aug 2024 6.0% serious AE View details

N/A N=1,041 Korean Post-marketing Surveillance for Xeljanz

Rheumatoid Arthritis · Psoriatic Arthritis
Primary: Number of Participants With Adverse Events (AEs), Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs) — 261; 148; 40…
Pfizer Results Aug 2024 4.0% serious AE View details